Evidence map›Paper›PMID 40418189›Full record

ArticleNucleic acid therapeutics2025

Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs.

Daniel O'Reilly, Raymond Furgal, Vignesh Hariharan, Clemens Lochmann, David Cooper, Dimas Echeverria, Anastasia Khvorova

Abstract read
In one paragraph

Article in Nucleic acid therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel O'ReillyRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Raymond FurgalRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Vignesh HariharanRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Clemens LochmannRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
David CooperRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Dimas EcheverriaRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Anastasia KhvorovaRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Funding

Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disordersR01NS104022 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2017 to 2026
$6.0M
Chemical engineering of therapeutic RNAs for extrahepatic deliveryR35GM131839 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2019 to 2026
$3.1M
Mid-Scale RNA Synthesis, Purification and Quality Control SystemS10OD020012 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2015 to 2015
$563k
NIGMS NIH HHS R35 GM131839NIH HHS R01 NS104022NIH HHS S10 OD020012
6 · The paper itself

Abstract

Chemically modified short interfering RNAs (siRNAs) unequivocally represent a groundbreaking class of drugs. The deliberate chemical modification of the natural structure has been pivotal to their resounding success. Specific modifications at certain positions bolster their potency, safety, stability, and specificity. In clinical research, 2'-

Indexed as

RiboseRNA, Small InterferingHumansOligonucleotidesRNA Stabilitylocked nucleic acidOligonucleotidesRiboseRNA, Small Interferingchemical modificationsgene silencingoligonucleotidessiRNA

Identifiers

PMID40418189
PMCPMC12167845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.